Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-29 7:01 pm Purchase | 2025-01-22 | 13G | Aadi Bioscience, Inc. AADI | Point72 Asset Management, L.P. | 1,470,311 6.000% | 1,470,311 (New Position) | Filing History |
| 2025-01-29 6:58 pm Purchase | 2025-01-22 | 13G | Ventyx Biosciences, Inc. VTYX | Point72 Asset Management, L.P. | 4,400,325 6.200% | 4,353,640 (+9325.56%) | Filing History |
| 2025-01-22 5:50 pm Purchase | 2025-01-21 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management, L.P. | 4,277,847 5.000% | 1,443,348 (+50.92%) | Filing History |
| 2025-01-14 4:53 pm Purchase | 2025-01-13 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management, L.P. | 4,820,333 5.600% | 1,617,952 (+50.52%) | Filing History |
| 2025-01-13 4:16 pm Purchase | 2025-01-10 | 13G | Array Technologies, Inc. ARRY | Point72 Asset Management, L.P. | 7,613,987 5.000% | 7,613,987 (New Position) | Filing History |
| 2025-01-06 4:10 pm Purchase | 2025-01-03 | 13G | Entera Bio Ltd. ENTX | Point72 Asset Management, L.P. | 2,701,560 6.800% | 2,701,560 (New Position) | Filing History |
| 2024-12-30 4:23 pm Purchase | 2024-12-27 | 13G | StoneCo Ltd. STNE | Point72 Asset Management, L.P. | 14,110,330 5.100% | 14,110,330 (New Position) | Filing History |
| 2024-12-20 4:05 pm Purchase | 2024-12-13 | 13G | Bicycle Therapeutics plc BCYC | Point72 Asset Management, L.P. | 4,230,302 8.900% | 3,209,134 (+314.26%) | Filing History |
| 2024-11-15 10:35 am Sale | 2024-09-30 | 13G | Terns Pharmaceuticals, Inc. TERN | Point72 Asset Management, L.P. | 2,894,093 3.500% | -1,027,133 (-26.19%) | Filing History |
| 2024-11-14 7:59 pm Purchase | 2024-09-30 | 13G | Cogent Biosciences, Inc. COGT | Point72 Asset Management, L.P. | 15,116,496 9.900% | 9,872,873 (+188.28%) | Filing History |
| 2024-11-14 7:59 pm Purchase | 2024-09-30 | 13G | Sphere Entertainment Co. SPHR | Point72 Asset Management, L.P. | 1,667,162 5.800% | 106,992 (+6.86%) | Filing History |
| 2024-11-14 7:58 pm Sale | 2024-09-30 | 13G | JOYY Inc. YY | Point72 Asset Management, L.P. | 43,659,720 5.400% | -1,670,180 (-3.68%) | Filing History |
| 2024-11-14 7:58 pm Purchase | 2024-09-30 | 13G | Agenus Inc. AGEN | Point72 Asset Management, L.P. | 23,974 0.100% | 23,974 (New Position) | Filing History |
| 2024-11-14 7:57 pm Purchase | 2024-09-30 | 13G | HUYA Inc. HUYA | Point72 Asset Management, L.P. | 163,579 0.200% | 163,579 (New Position) | Filing History |
| 2024-11-14 7:57 pm Sale | 2024-09-30 | 13G | Fox Corporation FOXA | Point72 Asset Management, L.P. | 70,800 0.100% | -11,975,318 (-99.41%) | Filing History |
| 2024-11-14 7:56 pm Sale | 2024-09-30 | 13G | Abeona Therapeutics Inc. ABEO | Point72 Asset Management, L.P. | 888,870 2.000% | -760,870 (-46.12%) | Filing History |
| 2024-11-14 7:55 pm Purchase | 2024-09-30 | 13G | Sagimet Biosciences Inc. SGMT | Point72 Asset Management, L.P. | 2,468,128 8.000% | 855,489 (+53.05%) | Filing History |
| 2024-11-14 7:55 pm Purchase | 2024-09-30 | 13G | Liberty Live Group LLYVA | Point72 Asset Management, L.P. | 1,576,057 6.200% | 288,908 (+22.45%) | Filing History |
| 2024-11-14 7:55 pm Sale | 2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Point72 Asset Management, L.P. | 2,300,643 2.900% | -1,116,257 (-32.67%) | Filing History |
| 2024-11-14 7:55 pm Sale | 2024-09-30 | 13G | MediWound Ltd. MDWD | Point72 Asset Management, L.P. | 11,727 0.100% | -809,773 (-98.57%) | Filing History |